A Phase Ib Study of SGN-40 (Anti-huCD40 mAb) in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Trial Profile

A Phase Ib Study of SGN-40 (Anti-huCD40 mAb) in Combination With Rituximab and Gemcitabine for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Completed
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2014

At a glance

  • Drugs Dacetuzumab (Primary) ; Gemcitabine; Rituximab
  • Indications Diffuse large B cell lymphoma
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 05 Aug 2010 Planned patient number (29) added as reported by ClinicalTrials.gov.
    • 05 Aug 2010 Actual end date (Feb 2010) added as reported by ClinicalTrials.gov.
    • 05 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top